

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.usplu.gov

APPLICATION NUMBER

FILING OR 371 (c) DATE

FIRST NAMED APPLICANT

ATTORNEY DOCKET NUMBER

10/789,684

02/27/2004

Alan L. Epstein

1920-325N1/09801297

000167 FULBRIGHT AND JAWORSKI L L P PATENT DOCKETING 29TH FLOOR 865 SOUTH FIGUEROA STREET

LOS ANGELES, CA 900172576

CONFIRMATION NO. 9775 FORMALITIES LETTER

OC000000012370417

Date Mailed: 04/15/2004

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE **DISCLOSURES**

Filing Date Granted

Applicant is given TWO MONTHS FROM THE DATE OF THIS NOTICE within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

 A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 CFR 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing." Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase Patentin Software, call (703) 306-2600
- For Patentin Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

Replies should be mailed to:

Mail Stop Missing Parts

Commissioner for Patents

P.O. Box 1450

Alexandria VA 22313-1450

Customer Service Center
Initial Patent Examination Division (703) 308-1202
PART 2 - COPY TO BE RETURNED WITH RESPONSE



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant

:Alan L. Epstein et al.

Serial No.

:10/789,684

Filed

:February 27, 2004

For

:VASOPERMEABILITY ENHANCING PEPTIDE

OF HUMAN INTERLEUKIN-2 AND **IMMUNOCONJUGATES THEREOF**

Docket No.: 1920-325N1/09801297

"Express Mail" Label No. EV 323472409 US

I hereby certify that this correspondence is being deposited with the U.S. Postal Service Express "Mail Post Office to Addressee" service under 37 CFR 1.10 on April 20, 2004 and is addressed to Mail Stop Missing Parts, Commissioner for Patents, P. O. BOX 1450, Alexandria, VA 22313-1450.

FULBRIGHT & JAWORSKI, L.L.P. 865 S. Figueroa Street, 29th Floor Los Angeles, CA 90017-2571

RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

MAIL STOP MISSING PARTS Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

In response to the Notice to Comply With Requirements for Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures mailed April 15, 2004, attached are the following:

- 1) Substitute computer readable form (CRF) copy of the "Sequence Listing";
- Paper copy of "Sequence Listing"; 2)
- Statement to Support Filings and Submissions in Accordance With 37 C.F.R. §§ 1.821 Through 1.825; and

4) A copy of the Notice to Comply With Requirements for Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures.

The Commissioner is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 50-0337, under Order No. 1920-325N1/09801297. A duplicate copy of this paper is enclosed. is enclosed.

Respectfully submitted,

Date: <u>April 20, 2004</u>

(213) 892-9206

MARGARET A. CHURCHILL, Ph.D. Registration No. 39,944